K.J. Harrison & Partners’s Inhibikase Therapeutics IKT Stock Holding History

K.J. Harrison & Partners’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,050	Closed	-$17K	–	238
2022 Q3	$17K	Hold	3,050	–	–	0.01%	174
2022 Q2	$14K	Buy	3,050 +1,167	+62%	+$6.88K	﹤0.01%	206
2022 Q1	$17K	Hold	1,883	–	–	﹤0.01%	290
2021 Q4	$17K	Buy	+1,883	New	+$20.8K	﹤0.01%	344

Other funds holding IKT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

K.J. Harrison & Partners's IKT Position: Q4 2022 in Review

K.J. Harrison & Partners sold out of Inhibikase Therapeutics (IKT) in Q4 2022, closing a stake of 3,050 shares — an estimated $17K sold.

K.J. Harrison & Partners first reported a position in IKT in Q4 2021 and held it in 4 quarters. The position peaked at $17K in Q3 2022. 19 funds tracked by Wall St. Rank hold IKT as of Q4 2022.

K.J. Harrison & Partners reported no remaining Inhibikase Therapeutics position as of Q4 2022 after selling out during the quarter.
K.J. Harrison & Partners sold 3,050 Inhibikase Therapeutics shares in Q4 2022, an estimated $17K.
K.J. Harrison & Partners first reported a position in Inhibikase Therapeutics in Q4 2021 and held it in 4 quarters.
K.J. Harrison & Partners's Inhibikase Therapeutics position peaked at $17K in Q3 2022.
19 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2022.

Based on K.J. Harrison & Partners's 13F filing for Q4 2022, filed 25 Jan 2023.